SCR7, a potent cancer therapeutic agent and a biochemical inhibitor of nonhomologous DNA end‐joining
Background DNA double‐strand breaks (DSBs) are harmful to the cell as it could lead to
genomic instability and cell death when left unrepaired. Homologous recombination and …
genomic instability and cell death when left unrepaired. Homologous recombination and …
Identification and characterization of novel SCR7‐based small‐molecule inhibitor of DNA end‐joining, SCR130 and its relevance in cancer therapeutics
Targeting DNA repair with small‐molecule inhibitors is an attractive strategy for cancer
therapy. Majority of DNA double‐strand breaks in mammalian cells are repaired through …
therapy. Majority of DNA double‐strand breaks in mammalian cells are repaired through …
Autocyclized and oxidized forms of SCR 7 induce cancer cell death by inhibiting nonhomologous DNA end joining in a Ligase IV dependent manner
Nonhomologous DNA end joining (NHEJ) is the major DNA double‐strand break (DSB)
repair pathway in mammals. Previously, we have described a small molecule inhibitor, SCR …
repair pathway in mammals. Previously, we have described a small molecule inhibitor, SCR …
Inhibition of nonhomologous end joining to increase the specificity of CRISPR/Cas9 genome editing
SV Vartak, SC Raghavan - The FEBS journal, 2015 - Wiley Online Library
DNA repair, one of the fundamental processes occurring in a cell, safeguards the genome
and maintains its integrity. Among various DNA lesions, double‐strand breaks are …
and maintains its integrity. Among various DNA lesions, double‐strand breaks are …
NHEJ inhibitor SCR7 and its different forms: Promising CRISPR tools for genome engineering
The CRISPR-Cas system currently stands as one of the best multifaceted tools for site-
specific genome engineering in mammals. An important aspect of research in this field …
specific genome engineering in mammals. An important aspect of research in this field …
Water-soluble version of SCR7-pyrazine inhibits DNA repair and abrogates tumor cell proliferation
Aim: Mammalian DNA Ligases play pivotal role in processes such as DNA replication,
recombination, and repair, which qualifies them as potent therapeutic targets to eradicate …
recombination, and repair, which qualifies them as potent therapeutic targets to eradicate …
[HTML][HTML] An inhibitor of nonhomologous end-joining abrogates double-strand break repair and impedes cancer progression
DNA Ligase IV is responsible for sealing of double-strand breaks (DSBs) during
nonhomologous end-joining (NHEJ). Inhibiting Ligase IV could result in amassing of DSBs …
nonhomologous end-joining (NHEJ). Inhibiting Ligase IV could result in amassing of DSBs …
SCR7, an inhibitor of NHEJ can sensitize tumor cells to ionization radiation
Nonhomologous end joining (NHEJ), one of the major DNA double‐strand break repair
pathways, plays a significant role in cancer cell proliferation and resistance to radio and …
pathways, plays a significant role in cancer cell proliferation and resistance to radio and …
Increasing the efficiency of CRISPR/Cas9-mediated precise genome editing in rats by inhibiting NHEJ and using Cas9 protein
Y Ma, W Chen, X Zhang, L Yu, W Dong, S Pan… - RNA biology, 2016 - Taylor & Francis
Precise modifications such as site mutation, codon replacement, insertion or precise
targeted deletion are needed for studies of accurate gene function. The CRISPR/Cas9 …
targeted deletion are needed for studies of accurate gene function. The CRISPR/Cas9 …
Proximal binding of dCas9 at a DNA double strand break stimulates homology-directed repair as a local inhibitor of classical non-homologous end joining
YL Feng, SC Liu, RD Chen, XN Sun… - Nucleic Acids …, 2023 - academic.oup.com
In CRISPR/Cas9 genome editing, the tight and persistent target binding of Cas9 provides an
opportunity for efficient genetic and epigenetic modification on genome. In particular …
opportunity for efficient genetic and epigenetic modification on genome. In particular …